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Platelets to the Rescue? A Literature Review of the Safety and Efficacy of 
Platelet-Rich Plasma for Symptomatic Osteoarthritis of the Knee
Timothy Simonich PA-S; Daryl Sieg PA-C
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Osteoarthritis of the knee is one of the most common joint 
disorders in the United States with rising prevalence due to 
obesity and an aging population.
Regarding non-surgical approaches to management, there has 
been growing interest in the use of intra-articular injections 
with Platelet Rich Plasma (PRP). 
Research Question
Literature Review




–No severe long-term complications observed in any study
–Common Transient injection reactions: localized 
pressure, pain, swelling, tenderness
–CaCl2 may contribute to adverse effects
–Higher concentrations  of platelets and/or leukocytes may 
attribute to adverse effects
Efficacy
–There is evidence to suggest PRP improves pain stiffness 
and physical function for short-term (<6 months) 
management
–Multiple studies suggested that higher concentrations of 
PRP did not correlate with clinical outcomes. 
–Multiple  doses and/or cyclical injections as well as PRP 
preparations with concentrated growth factors may be 
advantageous for more substantial and longer term 
benefits.
Trends in Efficacy
–The influence of patient age on PRP effectiveness is 
controversial with conflicting  studies
–More favorable outcomes have been observed in those 
with mild-moderate osteoarthritis. 
–Multiple  doses and/or cyclical injections may not 
provide additional benefit for those with moderate to 
severe OA.
–Cole, Karas, Hussey, Pilz, & Fortier (2017) suggested that 
PRP may be more effective in those who are of healthy 
weight (BMI 18.5-24).
–Beselga Garcỉa-Escudero & Miguel Hernậndez Trillos 
(2015) suggested that cyclical doses of PRP in addition to 
therapeutic exercise may provide sustained improvement 
of pain and physical function for up to 2 years.
A comprehensive review of eighteen clinical control trials 
studies was performed.  The primary scope of this review 
focuses on outcomes related to safety (adverse events) and 
efficacy based on Western Ontario and McMaster University 
Osteoarthritis Index (WOMAC) .
Primary Research questions
In patients with symptomatic osteoarthritis of the knee,…
– is platelet rich plasma safe? 
–does platelet rich plasma improve pain, stiffness, and 
physical function? 
–does one injection versus more than one injection 
improve outcomes?
–are there trends in the type of PRP that is most effective? 
Utility & Application
–Outpatient setting/ <1hr
–Safety comparable to other intra-articular injections
– In those that fail traditional therapeutic management, the 
addition of PRP to other non-invasive modalities may be a 
great option for those wanting to delay or avoid joint 
replacement surgery
– Patients that are treated with antiplatelet medications 
should not receive PRP injections because these 
medications may inhibit or interfere with the platelet 
function and decrease efficacy
Cost
–The cost of PRP can range from $400-1500 with 
discounted rates for multiple or bilateral injections. 
–There is currently no insurance coverage for PRP 
injections, except for special circumstances involving 
workman’s compensation or motor vehicle insurances
The Future  of  PRP
– In the mist of overwhelming bias and inconsistencies in 
study designs and wide variability in PRP preparation, 
current literature may not provide strong evidence to 
influence changes to future national guideline 
recommendations
–As the application of PRP is still in its infancy, clinicians 
implementing PRP injections for OA of the knee should be 
expected to make changes in the method of preparation 
and administration in years to come as more clinical trials 
aim to improve safety and efficacy of PRP and define 
optimal preparation methods and clinical practice 
guidelines.
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Statement of the Problem
The use of Intra-articular PRP injections for symptomatic 
osteoarthritis of the knee is in its infancy there have been 
many problems with evaluating platelet-rich plasma in the 
literature including: poor and inconsistent study designs, 
differences in platelet separation techniques,  use of variety of 
measurement scales and indexes,  lacking objective quantity 
and quality of PRP  that was utilized.
In reflection ,current clinical guideline recommendations put 
forth by the American Academy of Orthopedic Surgeons 
(2013) does not recommend nor disapprove the use of IAI of 
PRP for the treatment of symptomatic OA of the knee .
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Background
TABLE B11
Study Total IAI # IAI (at each interval) IAI Interval (weeks) # Cycles Cycle Interval (weeks)
(Baltzer, Moser, Jansen, & Krauspe, 2009) 6 2 1 3 ‡
(Beselga Garcỉa-Escudero & Miguel Hernậndez Trillos, 2015) 4 1 1 Na Na
(Cerza et al., 2012) 4 1 1 Na Na
(Cole, Karas, Hussey, Pilz, & Fortier, 2017) 3 1 1 Na Na
(Duymus et al., 2017) 2 1 4 Na Na
(Filardo et al., 2012a) 4 1 3 Na Na
(Filardo et al., 2012b) 3 1 1 Na Na
(Filardo et al., 2015) 3 1 1 Na Na
(Gobbi, Lad, & Karnatziko, 2015) 3 1 4 Na Na
(Gobbi, Lad, & Karnatziko, 2015) ‼ 3 1 4 2 4
(Gormeli et al., 2017) 1 1 Na Na Na
(Gormeli et al., 2017) ‼ 3 1 1 Na Na
(Jang, Kim, & Cha, 2013) 1 1 Na Na Na
(Kon et al, 2011) 3 1 2 Na Na
(Lisi, 2018) 3 1 4 Na Na
(Patel, Dhillon, Aggarwal, Marwaha, & Jain, 2013) 1 1 Na Na Na
(Patel, Dhillon, Aggarwal, Marwaha, & Jain, 2013) 2 1 3 Na Na
(Reyegani et al., 2014) 2 1 4 Na Na
(Sampson, Reed, Silvers, Meng, & Mandelbaum, 2010) 3 1 4 Na Na
(Smith, 2016) 3 1 1 Na Na
(Spakova, Rosocha, Lacko, Harvanova, & Gharaibeh, 2012) 3 1 1 Na Na
‡= insufficient data. Na= Not applicable. ‼= 2nd group in study
Table A5
Study Classification Anticoagulant Activation
(Baltzer, Moser, Jansen, & Krauspe, 2009) LP-PRP or LR-PRP* with IL-1Ra Yes† ‡
(Beselga Garcỉa-Escudero & Miguel Hernậndez Trillos, 2015) LP-PRP* or LR-PRP*  Yes† No
(Cerza et al., 2012) LP-PRP Sodium citrate ‡
(Cole, Karas, Hussey, Pilz, & Fortier, 2017) LP-PRP No No
(Duymus et al., 2017) LP-PRP Yes† ‡
(Filardo et al., 2012a) ‼ PRGF (LP-PRP*) and LR-PRP Yes† CaCl2
(Filardo et al., 2012b) LR-PRP Yes† ‡
(Filardo et al., 2015) LP-PRP or LR-PRP* Yes† CaCl2
(Gobbi, Lad, & Karnatziko, 2015) LP-PRP ‡ Collagen or Von Willebrand Factor
(Gormeli et al., 2017) LP-PRP or LR-PRP* Sodium citrate CaCl2
(Jang, Kim, & Cha, 2013) LP-PRP or LR-PRP* ACD-A No
(Kon et al, 2011) LR-PRP* Yes† CaCl2
(Lisi, 2018) LP-PRP* ACD-A Calcium gluconate
(Patel, Dhillon, Aggarwal, Marwaha, & Jain, 2013) LP-PRP* CPD-A1 CaCl2
(Reyegani et al., 2014) LR-PRP ACD-A No
(Sampson, Reed, Silvers, Meng, & Mandelbaum, 2010) LP-PRP* ACD-A Bovine thrombin + CaCl2
(Smith, 2016) LP-PRFM No No
(Spakova, Rosocha, Lacko, Harvanova, & Gharaibeh, 2012) LR-PRP* Sodium citrate No
PRP=Platelet-Rich Plasma, PRFM= Platelet-Rich Fibrin Matrix PRGF= Plasma Rich in Growth Factors, LP= Leukocyte-Poor, LR= Leukocyte-Rich
CPD-A1= Citrate Phosphate Dextrose and Adenine, ACD-Citrate dextrose-A, IL-1Ra=interleukin-1 Receptor Agonist
*= Defined through analysis of reported preparation method with assistance from Dr. Launchbury
† =assumed from preparation method. ‡= Unknown; not enough information. ‼= Study has 2 types of ACS
Table A4
Study # Spins Spin 1 (speed, min) Spin 2 (speed, min) Spin 3 (Speed, min) Comments
(Baltzer, Moser, Jansen, & 
Krauspe, 2009) 1 † Na Na
IL-1Ra was added to final 
product. 
Platelets were frozen for 
subsequent injections
(Beselga Garcỉa-Escudero & 
Miguel Hernậndez Trillos, 
2015) 1 3000 G, 10 Na Na
Platelets incubated 37 
degrease Celsius for 6 hours,
filtered, then frozen for 
subsequent injections
(Cerza et al., 2012) † † † † preparation not discussed
(Cole, Karas, Hussey, Pilz, & 
Fortier, 2017) 1 1500 rpm, 5 Na Na
(Duymus et al., 2017) 1 3700 rpm, 7 Na Na
Platelets may have been 
frozen (not specified) for
subsequent injections
(Filardo et al., 2012a) 1 580 rpm, 8 Na Na
Platelets were frozen for 
subsequent injections
(Filardo et al., 2012a)‼ 2 1800 rpm, 15 2500 rpm, 10 Na
Platelets were frozen for 
subsequent injections
(Filardo et al., 2012b) 2 1480 rpm, 6 3400 rpm, 15 Na
Platelets were frozen for 
subsequent injections
(Filardo et al., 2015) 2 1480 rpm, 6 3400 rpm, 15 Na
Platelets were frozen for 
subsequent injections
(Gobbi, Lad, & Karnatziko, 
2015) 1 3500 rpm, 5 Na Na
Prolonged cycles of PRP were 
injected
(1 IAI per month/ 3-month 
interval). 
(Gormeli et al., 2017) 2 1500 rpm, 6 3500 rpm, 12 Na
Platelets were frozen for 
subsequent injections
(Jang, Kim, & Cha, 2013) † † † †
Magellen autologous platelet 
separator
(Kon et al, 2011) 2 1480 rpm, 6 3400 rpm, 14 Na
Platelets were frozen for 
subsequent injections
(Lisi, 2018) 1 900 rpm, 7 min Na Na
Leukocyte removal was not 
discussed
(Patel, Dhillon, Aggarwal, 
Marwaha, & Jain, 2013) 1 1500 rpm, 15 Na Na Leukocytes removed with filter
(Reyegani et al., 2014) 2 1600 rpm, 15 2800 rpm, 7 Na
(Sampson, Reed, Silvers, 
Meng, & Mandelbaum, 2010) 1 1700 G, 15 Na Na
Platelets may have been 
frozen (not specified) for 
subsequent injections
(Smith, 2016) 1 1500 rpm, 5 Na Na Leukocytes removed with filter
(Spakova, Rosocha, Lacko, 
Harvanova, & Gharaibeh, 
2012) 3 3200 rpm, 15 1500, 10 3200, 10
Rpm- revolutions per minute. G= g-force. Na= Not applicable. †= Insufficient data. ‼= 2nd ACS group in study
Table A3
Study Reported Adverse Effects
(Baltzer, Moser, Jansen, & Krauspe, 2009)
Localized pressure, pain, swelling, tenderness, and heat that lasted up to 2 
days
(Beselga Garcỉa-Escudero & Miguel Hernậndez Trillos, 2015) No severe adverse effects
(Cerza et al., 2012) No observed adverse reactions
(Cole, Karas, Hussey, Pilz, & Fortier, 2017) †
(Duymus et al., 2017) †
(Filardo et al., 2012a)
No severe adverse events observed. Transient pain and swelling in both 
groups with more incidence in double spin group
(Filardo et al., 2012b) Minor events. Mild pain and effusion
(Filardo et al., 2015)
Transient post injection pain and swelling.
(Gobbi, Lad, & Karnatziko, 2015) †
(Gormeli et al., 2017) ‡
(Jang, Kim, & Cha, 2013) †
(Kon et al, 2011) No observed adverse reactions
(Lisi, 2018) No side-effects observed 
(Patel, Dhillon, Aggarwal, Marwaha, & Jain, 2013)
Syncope, dizziness, headache, nausea, gastritis, sweating, tachycardia. 
Higher incidence in those that received 2 injections
(Reyegani et al., 2014)
Transient local pain and swelling with no significant complications
(Sampson, Reed, Silvers, Meng, & Mandelbaum, 2010)
There was modest pain persisting 1-week after injection with no long-term 
complications.
(Smith, 2016) No observed adverse reactions
(Spakova, Rosocha, Lacko, Harvanova, & Gharaibeh, 2012)
Mild pain which resolved after 2 days with no severe adverse events
†= Not discussed. ‡=Not discussed but has outcome measurement for adverse events
PRP by Study: Preparation, Activation, and Anticoagulation
Adverse Effects by Study
Symptom Relief 
Injections by Study: Number and Cycles
